



Microbicide Trials Network Research Prominent at 2018 HIV R4P

Researchers from the National Institutes of Health-funded [Microbicide Trials Network](#) (MTN) are presenting on a range of HIV prevention topics at the 2018 HIV Research for Prevention (HIV R4P) meeting in Madrid, Oct. 21-25. Twenty-five presentations and sessions focusing on MTN-related research will be part of the meeting. The following is a day-by-day schedule of the 2018 HIV R4P sessions and presentations involving MTN-affiliated research and experts.

SUNDAY, OCTOBER 21

Satellite Session: *Planning for Success: Next steps for dapivirine ring* (SA05)

14:00-17:00

Burdoes Room

MONDAY, OCTOBER 22

Satellite Session – *Love, Power and PrEP: Addressing relationship dynamics and intimate partner violence to promote successful HIV prevention for women and girls* (SA17)

12:00-15:00

Bristol Room

Satellite Session – *Accelerating a Labor of Love: Time to transform HIV prevention for pregnant and breastfeeding women* (SA11)

12:00-15:00

Estrasburgo Room

TUESDAY, OCTOBER 23

Plenary Session – *What Happens First: Understanding Susceptibility, Transmission and Early Infection* (PL02)

8:30-10:00

Auditorium

Untangling hormonal impacts on the vaginal microbiome and HIV acquisition risk

Sharon Achilles

Presentation Time: 9:30

Poster Session – Behavioral and Social Science Research (P03)

17:30-19:30

Poster Hall

Site approaches to working with participant concerns regarding hair collection: Kampala site experience with women in MTN 025/hope, the dapivirine ring trial

Joselyne Nabisere

Poster (P03.11)

Ensuring potential volunteers are the “right fit” for study participation: Insights from the CAPRISA eThekweni clinical research site

Kalendri Naidoo

Poster (P03.15)

Intimate partner violence and engagement in the HIV care continuum among women in sub-Saharan Africa: A prospective cohort study

Sarah Roberts

Poster (P03.15)

Acceptability and feasibility of CHARISMA: Results of a pilot study

Ellen Wilson

Poster (P03.53)

Poster Session – Clinical Trial Results (P05)

17:30-19:30

Poster Hall

Potential causes for decreased enrollment of acutely infected participants in the ASPIRE trial

Edward Livant

Poster (P05.09)

Characteristics of women who enrolled into an open label extension trial of the dapivirine intravaginal ring for HIV-1 prevention

Nyaradzo Mavis Mgodli

Poster (P05.03)

Poster Session – Community Engagement in Prevention Research (P06)

17:30-19:30

Poster Hall

Benefits of prescreening workshops on participants’ understanding of choice, adherence and open reporting concepts in MTN-025/HOPE study: Kampala site experience

Doreen Kemigisha

Poster (P06.07)

Poster Session – Delivery Technologies: Novel Approaches, Formulation and Multi-purpose (P09)
17:30-19:30
Poster Hall

Embracing medidata rave in the 21st century: Tips to successful implementation
Justine Nakyeeyune
Poster (P09.09)

Poster Session – Epidemiology of HIV (P11)
17:30-19:30
Poster Hall

Risk factors for HIV-1 acquisition among 18-21 year-old South African women
Jennifer Balkus
Poster (P11.01)

Poster Session – Implementation Science, Including Structural Interventions, PrEP & VMMC (P14)
17:30-19:30
Poster Hall

Fidelity monitoring to ensure accurate implementation of an evidence-based adherence counseling intervention in MTN-025 (The HOPE Study)
Ivan Balan
Poster (P14.13)

Measuring HEART: Validity of a HEAlthy Relationships Assessment Tool to guide tailored counseling in the CHARISMA pilot study
Elizabeth Tolley
Poster (P14.33)

Poster Session – Product Acceptability and Adherence (P25)
17:30-19:30
Poster Hall

From theory to practice: Implementation of client centered adherence counselling at the Kampala site for the HOPE study
Aisha Zalwango
Poster (P25.03)

WEDNESDAY, OCTOBER 24

Plenary Session – The Future is Now: Next Steps in Developing New Prevention Options (PL03)
8:30-10:00
Auditorium

On-demand topical agents for HIV pre-exposure prophylaxis
Craig Hendrix
Presentation Time: 9:00

Oral Presentation Session – Contraception and HIV Risk: Still Between a Rock and a Hard Place

13:00-14:30

Londres Room

Safety and pharmacokinetics of dapivirine and levonorgestrel vaginal rings for multipurpose prevention of HIV and pregnancy

Sharon Achilles

Presentation time: 13:15

Risk of HIV-1 acquisition among South African women using a variety of contraceptive methods in a prospective study

Thesla Palanee-Phillips

Presentation time: 14:15

Poster Session – Community Engagement in Prevention Research (P06)

17:30-19:30

Poster Hall

Innovative Approaches for the effective Recruitment of former trial participants for an Open label trial: MTN 025/HOPE study; How the Kampala team did it!

Sophie Clare Nanziri

Poster (P06.06)

Poster Session – Contraception, Pregnancy and HIV Prevention (P07)

17:30-19:30

Poster Hall

Dapivirine vaginal ring use and cervical cytology abnormalities: Data from the placebo-controlled MTN-020/ASPIRE trial

Krishnaveni Reddy

Poster (P07.10)

Poster Session – Microbiome & STI: Impact on Prevention (P17)

17:30-19:30

Poster Hall

Impact of the dapivirine vaginal ring on the vaginal microbiota of adolescents, post-menopausal women and lactating women

Sharon Hillier

Poster (P17.02)

Poster Session – Transmission of HIV (P28)

17:30-19:30

Poster Hall

Heterosexual anal intercourse practices and associated HIV risk in two recent cohort studies in Eastern and Southern Africa

Romain Silhol

Poster (P28.02)

THURSDAY, OCTOBER 25

Oral Presentation Session – Opinion 360: Meaningful Engagement from Research to Roll Out

8:30-10:00

Oxford Room

Ethical considerations while involving adolescents aged 16-17 in HIV prevention clinical trials:

Community perspectives from Uganda

Rita Nakalega

Presentation Time: 9:00

Oral Presentation Session – Great Expectations: The Impact of PrEP

10:30-12:00

Marsella, Burdeos & Estrasburgo Rooms

Sensitive next-generation sequencing of HIV-1 from seroconverters in the MTN-020/ASPIRE dapivirine vaginal ring study

Urvi Parikh

Presentation time: 10:45